Clinuvel PharmaceuticalsASX:CUV -0.10%86 Return-on-Tangible-Equity is 8.53% as of Dec. 2025, which is 63% below its 10-year median of 23.32. GuruFocus rates ASX:CUV with a GF Score™ of 86/100 and a GF Value™ of A$17.75 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,195 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 88.79% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Clinuvel Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2025 was A$20.89 Mil. Clinuvel Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$244.73 Mil. Therefore, Clinuvel Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 8.53%.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
ASX:CUV'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -21.75 Med: 23.32 Max: 40.93
Current: 13.82
During the past 13 years, Clinuvel Pharmaceuticals's highest Return-on-Tangible-Equity was 40.93%. The lowest was -21.75%. And the median was 23.32%.
ASX:CUV's Return-on-Tangible-Equity is ranked better than 88.79% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs ASX:CUV: 13.82
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Clinuvel Pharmaceuticals Return-on-Tangible-Equity Related Terms
Clinuvel Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Clinuvel Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CUV vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.53% mean?
Clinuvel Pharmaceuticals (ASX:CUV) has a Return-on-Tangible-Equity of 8.53% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 63% below median its historical median of 23.32. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #134 out of 1195 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Clinuvel Pharmaceuticals' Return-on-Tangible-Equity too high?
Clinuvel Pharmaceuticals' current Return-on-Tangible-Equity of 8.53% is 63% below median its 10-year median of 23.32. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #134 out of 1195 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #134 out of 1195 companies for Return-on-Tangible-Equity. This places Clinuvel Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Return-on-Tangible-Equity is 8.53%, which is 63% below median its own 10-year median of 23.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.75, compared to a current price of A$10.28 — trading 42.1% below its estimated fair value. The current Return-on-Tangible-Equity is 8.53%, which is 63% below median its 10-year median of 23.32. Clinuvel Pharmaceuticals' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Return-on-Tangible-Equity is 8.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.28 is trading 42.1% below its estimated GF Value™ of A$17.75.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
Return-on-Tangible-Equity: 8.53% (63% below median its 10-year median of 23.32)
GF Value™: A$17.75 vs. price of A$10.28 (42.1% below fair value)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
86GF Score
Get the complete analysis for ASX:CUV
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
